Business Wire

Duravant Completes Acquisition of Pattyn

28.5.2025 19:44:00 CEST | Business Wire | Press Release

Share

Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the protein processing, food sorting and handling, packaging, and material handling sectors, announced the completion of its acquisition of the Pattyn Group BV (“Pattyn”), a leading manufacturer of packaging automation systems headquartered in Bruges, Belgium. The transaction was first announced on February 7, 2025, and was completed today.

With over 70 years of expertise, Pattyn is a trusted partner for companies looking to automate bulk packaging operations in industries ranging from food and ingredients to non-food applications. Pattyn has been a world-renowned brand specializing in bag-in-box packaging technology, and their comprehensive end-of-line solutions span the entire packaging process from case erecting and bag inserting to weigh filling, bag and case closing, and palletizing.

“We are extremely excited to welcome Pattyn to the Duravant family,” said Mike Kachmer, Chairman and CEO of Duravant. “Pattyn’s robust portfolio of high-quality packaging technologies and their steadfast focus on delivering value-driven solutions align perfectly with Duravant’s commitment to customer success. This partnership opens up incredible opportunities for collaboration with our Operating Companies across Duravant, enhancing our ability to serve a global customer base with innovative and reliable automation solutions.”

With six specialized manufacturing sites across Belgium, France, and Spain, Pattyn designs, builds and customizes fully integrated solutions backed by comprehensive end-to-end support. Along with their sales and service divisions in North America and Asia, Pattyn provides lifetime resources for equipment and consumables to customers in five continents.

“Pattyn shares Duravant’s culture and customer focused mindset, and we see tremendous opportunity to advance our strategic priorities at unprecedented speed,” said Stan Pattyn who leads the company. “Duravant’s global reach and foothold in fast-growing end markets such as protein processing creates a powerful platform for further expansion and innovation. We’re also excited to leverage the investments Duravant is making in emerging markets such as Brazil, Mexico, Thailand, China and India to better support customers in those regions.”

“As customers around the world strive for smarter, safer, and more efficient production, Pattyn continues to lead the way with packaging systems that meet the demands of today and the challenges of tomorrow,” said Mike Kachmer. “Their ability to innovate and adapt has been at the core of their success.”

Pattyn’s Industry Leading Portfolio

Pattyn’s core expertise lies in bag-in-box solutions with bag sealing, case erecting, case closing, and palletizing. From high-performance bagmaker-inserters for made-to-measure bags or compact units for pre-made bags on a reel, Pattyn ensures every bag fits perfectly into its container.

Pattyn provides specialized weigh filling solutions for semi-liquids, bulk solids, butter, tobacco and other products. Through advanced software, Pattyn produces fixed-weight boxes ensuring precise weight accuracy.

Through their dedicated Bakery Division, Pattyn designs high volume packaging lines for bread, pastry and frozen dough with cutting-edge counting and picking solutions that use 3D vision and robotic pick & place technology to accurately count and handle products.

Pattyn has specialized knowledge in designing and manufacturing large volume bag-in-box filling lines for big bags and octabins, primarily serving large-scale customers in (petro)chemical, food production and other industrial sectors.

About Duravant

Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales, and service facilities throughout North America, South America, Europe, and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end automation solutions for customers and partners through engineering and integration expertise, project management, and operational excellence. With worldwide sales distribution and support through the Duravant Lifecycle Services network, they provide immediate and lifetime aftermarket support to all the markets they serve in the protein processing, food sorting and handling, packaging, and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability, and reliability. For more information, visit www.duravant.com

About Pattyn

Headquartered in Bruges, Belgium, Pattyn Group is a manufacturer and service provider of innovative and highly engineered packaging automation equipment specializing in modular solutions for counting, weighing, filling, and bag-in-a-box applications. Since 1952, the company serves the B2B packaging segment and a diverse customer base that includes food and non-food producers in over 80 countries worldwide. Committed to fostering lifetime partnerships, Pattyn designs and delivers turnkey packaging lines with innovative modular designs that deliver custom solutions. The company provides aftermarket support with consumables, parts, and comprehensive service programs. With six manufacturing sites in Belgium, France, and Spain, and sales and service hubs in the United States and Asia, Pattyn partners with their customers to improve the efficiency, performance, and quality of their industrial packaging needs. For more information, visit www.pattyn.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250528586062/en/

Contacts

Eleni Yianas
Senior Vice President, Marketing
Duravant
Eleni.yianas@duravant.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye